in the absence of a submission from the holder of the marketing authorisation:
rituximab (MabThera®) is not recommended for use within NHSScotland.
Indication under review: treatment of patients with moderate to severe pemphigus vulgaris.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice354KB (PDF)
- Medicine name:
- rituximab (MabThera)
- SMC ID:
- Treatment of patients with moderate to severe pemphigus vulgaris.
- Pharmaceutical company
- BNF chapter
- Submission type
- Non submission
- Not recommended
- Date advice published:
- 13 May 2019